Corrigendum to: The EVAPORATE trial provides important mechanistic data on plaque characteristics that have relevance to the REDUCE-IT results and clinical use of icosapent ethyl
- PMID: 34151350
- DOI: 10.1093/eurheartj/ehab351
Corrigendum to: The EVAPORATE trial provides important mechanistic data on plaque characteristics that have relevance to the REDUCE-IT results and clinical use of icosapent ethyl
Erratum for
-
The EVAPORATE trial provides important mechanistic data on plaque characteristics that have relevance to the REDUCE-IT results and clinical use of icosapent ethyl.Eur Heart J. 2021 Aug 17;42(31):3025-3026. doi: 10.1093/eurheartj/ehab233. Eur Heart J. 2021. PMID: 33970207 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources